October 31, 2024
October 30, 2024
Axxam has built its reputation as a premier CRO by offering advanced expertise in assay development, hit identification including high-throughput screening, and hit-to-lead activities. While excelling in Central Nervous System (CNS)-related research, Axxam’s expertise spans all therapeutic areas. By adopting CDD Vault, Axxam aims to streamline data management, improving efficiency and accelerating timelines for its partners in the pharmaceutical and biotech industries.
Dr. Iolanda Micco, Head of Discovery Chemistry at Axxam, commented: “Supporting our clients from target validation to lead optimization, data management plays a pivotal role in the success of our research. CDD Vault provides us with a comprehensive platform to handle the complexity of integrated projects, ensuring that our scientific teams and clients can collaborate more effectively and make faster, informed decisions.”
CDD Vault is a cloud-based data management platform that facilitates the secure organisation and analysis of chemical and biological data. For Axxam, the adoption of this platform will allow researchers to centralise their data, share insights securely
with partners, and maintain full control of intellectual property. This integrated approach will significantly enhance Axxam’s capabilities in delivering high-quality research and drug discovery services.
Dr. Dario Gioia, Computational Chemist at Axxam and first-hand user of CDD Vault, highlighted the benefits of the platform:
“We are often requested to address very challenging projects that are inherently complex, requiring the management of vast amounts of detailed biological and chemical data. CDD Vault’s intuitive design and powerful functionalities will streamline our workflows, making data more accessible while maintaining the highest standards of security and confidentiality that our clients expect.”
This new platform adoption further supports Axxam’s commitment to advancing novel therapies, while offering enhanced research infrastructure to clients working on drug discovery.
“At CDD, we are delighted to see Axxam adopt CDD Vault to advance their commitment to innovation across a vast spectrum of life sciences. Axxam’s team exemplifies scientific excellence and versatility, in hit identification to lead generation,
supporting clients from biotech start-ups to global pharma" commented Dr Barry Bunin, CEO of Collaborative Drug Discovery. "With CDD Vault, Axxam gains a robust data platform tailored to their needs, designed to streamline and accelerate their discovery workflows. We are excited to support their novel research approach in life science fields, enabling them to continue pioneering discoveries across therapeutic, agricultural, and consumer markets”.
About Axxam
Axxam is a leading contract research organization (CRO) providing integrated early discovery services and solutions across the life sciences industries with headquarters located in Bresso (Milan, Italy). Within the drug discovery disciplines, Axxam supports pharma and biotech companies, start-ups, patient foundations as well as academic groups in their journey from target assessment and hit identification to lead generation over all therapeutic areas and target classes.
Axxam’s services include assay development, high-throughput screening and hit-to-lead. The same science-driven approach is also applied to identify new bioactive compounds for crop protection, animal health, food, beverage, pet food, cosmetic and perfume industries. For more information please visit www.axxam.com.
About CDD Vault
CDD Vault by Collaborative Drug Discovery is a cloud-based platform designed to manage chemical and biological data. It enables researchers to organise, analyse, and share scientific data in a secure and collaborative environment, optimising drug
discovery processes.
Tag(s):
News